Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Curis, Inc. - Common Stock (NQ:CRIS)

1.370 +0.120 (+9.60%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Curis, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Expert Ratings for Curis ↗
 
Via Benzinga
News headline image
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of... 
Via Benzinga
News headline image
Analyst Holds Steady On Curis As FDA Removes Partial Clinical Hold On Leukemia Study ↗
Thursday, the FDA removed the partial clinical hold on Curis Inc's (NASDAQ: CRIS) TakeAim Leukemia Phase 1/2 study of emavusertib  
Via Benzinga
News headline image
Why Curis (CRIS) Shares Are Nosediving Thursday ↗
Curis, Inc. (NASDAQ: CRIS) shares are trading lower by 8.29% to $0.75 Thursday morning after the company announced a $15.1 million registered direct offering. 
Via Benzinga
News headline image
Curis's Return On Capital Employed Overview ↗
 
Via Benzinga
News headline image
A Preview Of Curis's Earnings ↗
 
Via Benzinga
News headline image
Meta Platforms To Rally Over 14%? Here Are 10 Other Analyst Forecasts For Friday ↗
Needham raised the price target for Applied Digital Corporation (NASDAQ: APLD) from $8.5 to $16. Needham analyst John Todaro maintained a Buy rating. Applied Digital shares fell 14.2% to close at $7.70... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Preview For Curis ↗
 
Via Benzinga
News headline image
Why Hertz Global Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket ↗
Gainers Secoo Holding Limited (NASDAQ: SECO) rose 44% to $1.44 in pre-market trading after dipping over 31% on Friday. 
Via Benzinga
Looking Into Curis's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Why Is Curis (CRIS) Stock Up 20% Today? ↗
Curis just received a regulatory nod for its lymphoma treatment study from the FDA. Now CRIS stock traders are buying today. 
Via InvestorPlace
News headline image
FDA Clears Curis' Lymphoma Study, Keeping Leukemia Trial Still Stalled ↗
 
Via Benzinga
News headline image
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial. 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday's Mid-Day Session ↗
Gainers HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) shares jumped 165.7% to $1.4350 after jumping around 118% on Friday. HTG Molecular Diagnostics, last month, posted a Q3 loss of $0.41 per share. 
Via Benzinga
News headline image
Earnings Outlook For Curis ↗
Curis (NASDAQ:CRIS) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement. Analysts estimate that Curis will report an... 
Via Benzinga
News headline image
Why Golden Ocean Group Is Trading Higher By 7%; Here Are 28 Stocks Moving Premarket ↗
Gainers 
Via Benzinga
News headline image
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Curis Resumes Enrollment In Monotherapy TakeAim Leukemia Study, Combo Phase Still Under Partial Hold ↗
The FDA has notified Curis Inc (NASDAQ: CRIS) to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study of Emavusertib. 
Via Benzinga
News headline image
Curis's Return On Capital Employed Insights ↗
According to Benzinga Pro data, during Q2, Curis (NASDAQ:CRIS) posted sales of $2.39 million. Earnings were up 1.05%, but Curis still reported an overall loss of $15.94 million. 
Via Benzinga
News headline image
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Analyzing Curis Short Interest ↗
Curis (NASDAQ:CRIS) short percent of float has fallen 4.29% since its last report. The company recently reported that it has 3.58 million shares sold short, which is... 
Via Benzinga
News headline image
This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday ↗
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares climbed 135.9% to close at $2.17 on Thursday. 
Via Benzinga
News headline image
Dow Falls 60 Points; Crude Oil Rises Sharply ↗
U.S. stocks traded mixed toward the end of trading, with the Dow Jones dropping around 60 points on Thursday. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
  
Via Benzinga
News headline image
Why Plus Therapeutics Is Trading Higher By Over 50%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 297% to $3.66. 
Via Benzinga
News headline image
BLUE Stock Moves as FDA Approves Bluebird Bio’s Gene Therapy ↗
Bluebird Bio (BLUE) stock is on the move Thursday following FDA approval for beta-thalassemia treatment ZYNTEGLO in adults and children. 
Via InvestorPlace
News headline image
U.S. Stocks Turn Higher; Nasdaq Rises 50 Points ↗
U.S. stocks turned higher midway through trading, with the Nasdaq Composite gaining 50 points on Thursday. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
  
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.